Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.

Revenue
+4.29%
EPS
+2.17%
Free cash flow
+27.0%
Total debt
−18.1%

Quarter to September 2026, against a year earlier

150.97 8.46 −5.31%
Market cap
$16.8B
P/E
71.9×
Fwd P/E
66.2×
Dividend yield
0.19%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100

Revvity Inc. 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 28, 2025 · Filed · accepted 4:10 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 25, 2025: 41 added · 15 removed · 74 modified; 3 with only figures updated; 7 moved without change

  1. Added · Our Strategy

    •Advancing the use of Artificial Intelligence (“AI”) to further strengthen our differentiated offerings and to drive internal operating efficiencies;